Brain+ updates on implementation and scaling activities for its CST-Assistant in Denmark

Copenhagen, Denmark, May 2, 2024 – Brain+ A/S (Nasdaq First North: BRAINP)  

• Upcoming v2.0 of the CST-Assistant is showcased today at the Dementia Days (2-3 May) 2024, the 3rd time Brain+ features at this primary annual dementia event in Denmark  

• Danish usability study of the CST-Assistant with 5 municipalities and VIA University College completed in Q1 2024 with positive feedback and user insights being incorporated into v2.0   

• Building on growing CST adoption, its pipeline of sales leads, show-casing and planned release of an upgraded CST-Assistant v2.0, Danish sales are expected to increase in 2024  

• The DKK 3.5 million grant funded DK project for implementation and scaling of the CST-Assistant, partnered with 6 municipalities, the Danish Alzheimer’s Association and the DanAge Association, has advanced to CST therapist education and product implementation   

• The CST-Assistant is being integrated into the official CST education for new therapists. The 2nd iteration of the ‘integrated CST education’ now starts being tested in the CO-PI project   

Brain+ show-case and poster of upcoming v2.0 of the CST-Assistant at the Danish Dementia Days
Today, the annual dementia summit, Dementia Days, kicks off in Copenhagen (2-3 May). The summit has participation of over 1,000 dementia health care professionals and other relevant stakeholders from the Danish dementia eco-system, including dementia coordinators, -consultants, and - leaders. Throughout the conference program, the foundational role of Cognitive Stimulation Therapy (CST) for dementia is prominently highlighted. CST is the main therapy delivered by Brain+ software-based CST products. The growing focus on and recognition of the role of CST in dementia management act as a catalyst for generating customer interest in the CST-Assistant (renamed for UK entry from formerly CST-Therapist Companion).

For Brain+'s Danish go-to-market activities, this conference therefore represents the pinnacle event of the year. It serves as a crucial platform for re-connecting with customers and customer leads and for building relationships. It is also the optimal event for showcasing the upgraded v2.0 of the CST-Assistant, which the company has been developing through 2023 and into 2024. The results of the usability study of the CST-Assistant v2.0 with VIA University College (see below) is presented with a scientific poster, serving to build brand and credibility with the target audience present at the conference.

Positive usability study
The usability study of the digital therapist support tool concluded successfully, with positive feedback and valuable insights garnered from participants in the 5 participating municipalities. This study marked an important step in the product development process, providing essential data and user perspectives that were instrumental in refining and enhancing the second version of the product that will be launch in Denmark in Q2 and in UK in Q3. The constructive feedback received from users allowed for the identification of strengths and areas for improvement, enabling the development team to implement targeted enhancements to the tool's functionality, usability, and overall user experience. As a result, the second version of the product not only addresses the needs and preferences of therapists more effectively, but also reflects the commitment to continuous improvement and user-centric design principles. 

Danish market outlook
In the Danish municipal sales cycle, the first half of the year is typically used to identify relevant new product and service solutions, while the second half is for budgeting and buying. Product awareness and customer relationship building are thus expected to convert into paying customer contracts and sales towards the end of the year. The primary role of the Danish home market in the go-to-market strategy has been to test and develop the products, prove the demand, and prepare the product for successful UK entry based on live use from Danish therapists. All of this has been achieved, and Denmark, while still growing commercially, will continue to serve this function going forward, while the UK is the growth market where Brain+ will derive the large majority of its revenues in 2025-2026.
Q2 is the ‘beauty contest’ quarter in public procurement cycle, as every year, municipal sales are expected in Q4. Brain+ expects up to 5 more municipal sales this year.

CO-PI project for implementing CST-Assistant begins practical implementation stage
In 2023 Brain+ received approval for receiving DKK 3.5million funding to implement its CST-Assistant product in six Danish municipalities (Odense, Frederecia, Guldborgsund, Viborg, Tårnby, Solrød), and influential NGOs focused on dementia and healthy ageing: the DanAge (Ældresagen), the Danish Alzheimer’s Association and Konsulatet for Fællesskab. The purpose of the project for Brain+ is three-fold: 1) to expand its commercial traction by funding initially implementation of its product via grants to later convert to paid contracts, 2) to develop a rigourous and effective implementation model (which is a key success factor in public health commercialization), 3) to refine and test the integration of the CST-Assistant into the CST-education of new CST Therapists. The initial coordination and onboarding phase is completed and the municipal therapists will now be trained in both CST- and the CST-Assistant. Having the CST-Assistant as an integrated part of the CST education, makes it the de facto standard for delivering CST, and greatly strengthens the competitive position of Brain+. The first iteration of this integrated education was tested in the Danish usability study, and now the 2nd iteration will be tested in the CO-PI project.   


Contact Information
Kim Baden-Kristensen, CEO and Co-founder
Mobile: + 45 31393317 (SMS)
E-mail: [email protected]  

Brain+ mission:  Become the global health tech provider in dementia management, offering certified therapeutic software solutions and servicing several million people affected by dementia by 2030.